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ABSTRACT 
The mu1 opioid receptor gene, OPRM1, has long been a high-priority candidate for human 
genetic studies of addiction. Because of its potential functional significance, the non-
synonymous variant rs1799971 (A118G, Asn40Asp) in OPRM1 has been extensively studied, 
yet its role in addiction has remained unclear, with conflicting association findings. To resolve 
the question of what effect, if any, rs1799971 has on substance dependence risk, we conducted 
collaborative meta-analyses of 25 datasets with over 28,000 European-ancestry subjects. We 
investigated non-specific risk for “general” substance dependence, comparing cases dependent 
on any substance to controls who were non-dependent on all assessed substances. We also 
examined five specific substance dependence diagnoses: DSM-IV alcohol, opioid, cannabis, and 
cocaine dependence, and nicotine dependence defined by the proxy of heavy/light smoking 
(cigarettes-per-day > 20 versus ≤ 10). The G allele showed a modest protective effect on general 
substance dependence (OR = 0.90, 95% C.I. [0.83-0.97], p-value = 0.0095, N = 16,908). We 
observed similar effects for each individual substance, although these were not statistically 
significant, likely because of reduced sample sizes. We conclude that rs1799971 contributes to 
mechanisms of addiction liability that are shared across different addictive substances. This 
project highlights the benefits of examining addictive behaviors collectively and the power of 
collaborative data sharing and meta-analyses. 
KEY WORDS: Addiction; substance dependence; OPRM1; opioid receptor; single nucleotide 
polymorphism (SNP); genetic association 
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1. INTRODUCTION 
The mu opioid receptors are part of a family of G protein-coupled receptors that are expressed in 
the brain and bind endogenous and exogenous opioids. The mu1 opioid receptor gene (OPRM1) 
has been one of the most studied genes in psychoactive substance research. It is a receptor for 
opioid analgesic agents and is involved in reward and analgesic pathways (Kreek and Koob 
1998). The non-synonymous single nucleotide polymorphism (SNP) rs1799971 (A118G) in exon 
1 of OPRM1 causes an asparagine to aspartic acid substitution at the fortieth amino acid residue 
(Asn40Asp). The G (Asp) allele is the minor allele across multiple human populations, with 
frequencies ranging from 4% in African-American samples to ~16% in European-ancestry 
samples to over 40% in some Asian samples 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1799971). Multiple studies have 
examined the functional effects of this amino acid change on expression levels and receptor 
properties such as binding affinity and signaling (Befort et al. 2001;  Beyer et al. 2004;  Bond et 
al. 1998;  Deb et al. 2010;  Mague and Blendy 2010;  Mague et al. 2009;  Ray et al. 2012;  Wang 
et al. 2014;  Wang et al. 2012;  Zhang et al. 2005).  
Because of its potential functional significance, many human genetic studies of substance 
dependence have targeted rs1799971. However, the role, if any, of rs1799971 in substance 
dependence remains unclear (Crist and Berrettini 2013;  Levran et al. 2012;  Mague and Blendy 
2010). In studies of opioid dependence, results have been mixed, with the minor (G) allele 
reported to have no effect in some studies (Crowley et al. 2003;  Levran et al. 2008;  Nelson et 
al. 2014;  Nikolov et al. 2011) and to decrease risk in others (Bond et al. 1998;  Tan et al. 2003). 
Similarly, analyses of alcohol dependence have reported increased risk (Bart et al. 2005;  Kim et 
al. 2004), no effect (Bergen et al. 1997;  Rouvinen-Lagerstrom et al. 2013;  Sander et al. 1998;  
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Xuei et al. 2007), and decreased risk (Schinka et al. 2002;  Town et al. 1999) for this allele. 
Analyses of rs1799971 with other addictive substances also show no consensus (Clarke et al. 
2013;  Crist and Berrettini 2013;  Franke et al. 2001;  Gelernter et al. 1999;  Hardin et al. 2009;  
Munafo et al. 2013).  
Literature-based meta-analyses have evaluated the association of rs1799971 with substance 
dependence (Arias et al. 2006), opioid dependence (Coller et al. 2009;  Glatt et al. 2007;  Haerian 
and Haerian 2013), and alcohol dependence (Chen et al. 2012a). Three of these meta-analyses 
reported no association (Arias et al. 2006;  Coller et al. 2009;  Glatt et al. 2007), while among 
Asian samples the G allele was reported to increase risk for alcohol (Chen et al. 2012a) and 
opioid dependence (Haerian and Haerian 2013). Although these meta-analyses attained large 
samples by combining published information, they were subject to heterogeneity from multiple 
sources, including differing phenotypes, ascertainment schemes, and statistical analysis models 
across the meta-analyzed publications.  
To clarify the effect of rs1799971 on substance dependence risk, we conducted collaborative 
meta-analyses based on new analyses of multiple datasets. Our data-driven approach moves 
beyond the limitations of literature-based meta-analyses by (1) defining consistent phenotypes 
across studies, (2) performing new, uniform analyses across datasets as in our previous meta-
analyses (Chen et al. 2012b;  Hartz et al. 2012;  Saccone et al. 2010), and (3) inviting 
investigators to contribute analyses from established studies with relevant phenotype and 
genotype data, irrespective of prior publication on rs1799971.  
2. METHODS 
2.1. Samples and Study design 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
8 
 
Twenty-five datasets contributed a starting sample of 28,689 study participants of European 
ancestry. Invitations to participate were sent to all studies in the NIDA Genetics Consortium, 
which NIDA formed to facilitate collaboration among investigators in addiction genetics, as 
documented by the NIDA Center for Genetic Studies (https://nidagenetics.org/studies). We 
extended invitations to additional studies suggested by consortium members as likely to have 
relevant data, and to collaborators on a previous meta-analysis of smoking quantity and lung 
disease (Saccone et al. 2010). NIDA further advertised the opportunity to participate in this 
meta-analysis project with a web announcement at 
http://www.drugabuse.gov/researchers/research-resources/genetics-research-
resources/collaborative-opportunities-genetics-research. Dataset inclusion criteria were: (1) 
rs1799971 must have been genotyped, and (2) at least one of these five phenotypes must have 
been assessed: DSM-IV defined alcohol, cannabis, cocaine, or opioid dependence, or categorized 
cigarettes per day (CPD) (0-10, 11-20, 21-30, and 31+ CPD).  
Study participants with a history of abstinence from alcohol (never drank) were excluded prior to 
all analyses, so that included participants satisfied a minimum exposure to alcohol. For the main 
analyses, we filtered out study participants if they had no known substance dependence and were 
also under the age of 25. Thus, we included non-dependent (control) participants only if they 
were old enough to have passed through the period of highest risk, so as to reduce phenotypic 
misclassification. For each dataset, Table 1 gives demographic characteristics, the allele 
frequency of rs1799971, and key publications. Supplementary text S1 provides additional details 
for each dataset, including study recruitment, genotyping methods, and data quality control. 
2.2. Phenotypes 
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We analyzed six primary dichotomous phenotypes: a “general” substance dependence diagnosis 
(lifetime dependence on any of five substances: alcohol, nicotine, cannabis, cocaine, and 
opioids), plus the corresponding five individual substance-specific lifetime dependence 
diagnoses. General substance dependence controls were required to be non-dependent on all 
substances assessed in that dataset; not all studies assessed all five substances. For each 
substance, individuals who did not meet dependence criteria were classified as non-dependent; 
abuse criteria were not considered. These phenotypes allowed us to examine the general (non-
specific) liability to substance dependence and compare non-specific and substance-specific 
associations. 
DSM-IV criteria were used to define dependent cases for alcohol, cannabis, cocaine, and opioids. 
For nicotine dependence, we defined the proxy of heavy smoking cases (CPD > 20) and light 
smoking controls (CPD ≤ 10) for current and former smokers, based on CPD when they were 
smoking; if multiple measurements were available the maximum value was used. Heavy versus 
light CPD is more commonly measured than nicotine dependence and has been an informative 
proxy for nicotine dependence in large meta-analyses (Chen et al. 2012b;  Hartz et al. 2012;  
Saccone et al. 2010); smokers meeting this threshold strongly overlap with nicotine dependent 
smokers. Because CPD does not account for dependence items such as withdrawal (Lessov et al. 
2004), secondary analyses examined the effect of redefining general dependence using standard 
definitions of nicotine dependence (Fagerström Test for Nicotine Dependence (Heatherton et al. 
1991) and DSM-IV), in the subset of studies for which these were available. 
In addition to filtering out subjects who did not meet minimum exposure to alcohol, we also 
defined analysis variables for exposure to each of the other four substances. For cannabis, 
cocaine, and opioids, the exposure threshold was “at least one lifetime use.” For nicotine, we 
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used “at least 100 cigarettes smoked lifetime,” a commonly used threshold to define smoking 
exposure in epidemiological studies.  
Table 2 shows dataset-specific counts for cases, controls, and exposed controls. Individuals 
dependent on multiple substances are counted and analyzed in the corresponding multiple 
categories. 
2.3. SNP for analysis 
We required rs1799971 to be genotyped in each dataset. For analyses, we coded rs1799971 as 
the number of copies of the G (minor) allele.  
2.4. Statistical analyses and meta-analysis 
We conducted six correlated discovery tests corresponding to the six primary phenotypes: the 
general substance dependence diagnosis and the five specific substance dependence diagnoses. 
To limit the number of tests, we focused on testing for a main effect of rs1799971 on these 
outcomes. All discovery analyses filtered out study participants under the age of 25 with no 
known substance dependence to ensure that controls had passed the typical age of dependence 
onset; cases are dependent and thus have had sufficient exposure regardless of age. Additional 
interpretive tests examined the robustness and consistency of discovery test results, and included 
analyses without age filtering for comparison. 
To ensure uniform analyses across datasets, the coordinating site at Washington University 
developed analysis scripts in SAS® and R. Scripts were distributed to collaborating sites, which 
then analyzed their datasets locally. Results were returned to the coordinating site for meta-
analyses. We used standard inverse-variance-weighted meta-analysis as implemented in the 
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rmeta package in R (Lumley ;  R Development Core Team 2012). Additionally, to be included in 
the meta-analysis of a given model, each dataset was required to have at least five cases and five 
controls available. This requirement was intended to reduce noise when some subgroups became 
very small after phenotypic filtering. All samples included for general dependence in fact met a 
higher threshold of at least 20 cases and 20 controls. We report fixed effect estimates together 
with Cochran’s Q and I2 to evaluate heterogeneity for each meta-analyzed model. No significant 
heterogeneity was observed among the studies analyzed (p-value for Q > 0.05, Table S1 and 
Tables 3 and 4). Correspondingly, Q values were close to the respective degrees of freedom 
(number of studies) and I2 values were small with no values greater than 26% (Supplementary 
Table S1). 
2.5. General substance dependence analyses 
Logistic regression was used to estimate the effect of rs1799971 on general substance 
dependence with covariates for sex and age. Of the 25 available datasets, 20 had at least five 
cases (dependent at least one of the five substances) and five controls (no known substance 
dependence diagnoses and exposed to alcohol) for analysis of general substance dependence. 
Our interpretive tests examined the robustness of the general substance dependence results and 
compared them to substance-specific effects. Specifically, to assess the influence of each 
individual dataset, each of the 20 contributing datasets was, in turn, left out of the meta-analysis. 
In this leave-one-out test, observing consistency of summary odds ratios would suggest that it is 
unlikely that the overall meta-analysis result is primarily due to a single study. Also, we meta-
analyzed only studies that had assessed all five substances to examine consistency of results; the 
general dependence controls in these studies were assessed for all five substances and thus more 
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homogenous. Finally, to compare the effect of rs1799971 on general substance dependence 
liability with its effect on the constituent substance-specific diagnoses, we tested for association 
using individuals dependent on each specific substance as cases compared to the same controls 
used in the general dependence analysis (non-dependent on all assessed substances).  
2.6. Specific substance dependence analyses 
To test the association of rs1799971 with each specific dependence diagnoses while accounting 
for the remaining diagnoses, our primary analysis used ordinal logistic regression with additively 
coded rs1799971 as the dependent variable and the five dependence diagnoses, four exposures, 
sex, and age as explanatory variables. This model simultaneously estimates association of 
rs1799971 with each substance while accounting for co-morbidity (Grucza et al. 2008). This 
analysis used only the datasets that had all five substance dependence diagnoses and all four 
exposure variables because the model required that there be no missing variables. 
To interpret and examine the robustness of these results, we evaluated traditional logistic 
regression models on the same datasets, also accounting for co-morbidity: each specific 
substance dependence was tested as the outcome, with log-additively coded rs1799971, age, sex, 
and the remaining specific substance dependence diagnoses as explanatory variables. Here, cases 
were dependent on a given substance, and controls were exposed but not dependent on that 
substance regardless of diagnoses for the remaining four substances. Additionally, to test 
equivalence of regression coefficients from ordinal regression analyses of individual substances, 
we conducted a two sample t-test assuming unequal variance. 
To examine whether substance-specific results remained consistent with a larger number of 
datasets, we used all datasets that had assessed each substance for additional interpretive tests, 
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with the dependence diagnosis as outcome and additively coded rs1799971, sex, and age as 
explanatory variables.  
2.7. Multiple test correction 
To estimate the effective number of independent tests corresponding to the six correlated 
discovery tests, we used matSpD [http://gump.qimr.edu.au/general/daleN/matSpD/], which 
accounts for correlations among phenotypes (Cheverud 2001;  Li and Ji 2005;  Nyholt 2004). 
Using Pearson correlations among the five dependence diagnoses from the studies with all five 
phenotypes assessed (see Table S3), plus one additional test for general substance dependence, 
we obtained a conservative estimate of 5.1218 independent tests, corresponding to a Bonferroni-
corrected p-value threshold of 𝛼′ = 9.76 × 10−3 for statistical significance. 
3. RESULTS 
3.1. The G (Asp) allele of rs1799971 shows a modest protective effect on general substance 
dependence 
We observed a significant association between rs1799971 and general substance dependence 
(Figure 1). Based on 9064 cases and 7844 age-filtered controls from 20 datasets, the G allele 
showed a modest protective effect (OR = 0.90, 95% C.I. [0.83-0.97], p-value = 9.52 × 10−3, N = 
16,908); 15 of the 20 studies showed a protective direction of the G allele. Heterogeneity 
variance was not statistically significant (Q=20.13, p-value = 0.39). A secondary analysis that 
did not require controls to be over 25 years old yielded a similar odds ratio (OR = 0.90, 95% C.I. 
(0.84-0.98), N = 17,918), but was not statistically significant after multiple correction in this 
larger sample (p-value = 1.06 × 10−2), consistent with our hypothesis that it is important for 
controls to be past the typical age of risk.  
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Leave-one-out test of robustness yielded odds ratio estimates ranging from 0.88 to 0.92, with 
none of the 20 iterations showing significant heterogeneity. This tight range of ORs centered on 
the overall odds ratio indicates that our finding was not driven by a single dataset. Only a few of 
the individual iterations showed significant association (e.g. 4 of 20 when using 𝛼′ = 9.76 ×
10−3 as the significance threshold), likely due to the reduced sample size. 
To reduce potential heterogeneity among the general dependence controls, we meta-analyzed the 
10 datasets that had all five substance-specific dependence diagnoses and at least 5 cases and 5 
controls. For these 10 datasets (3947 cases and 2348 controls), the summary odds ratio was 0.87 
(p-value = 0.01), very similar to the discovery result based on 20 studies.  
Additionally, to aid interpretation, we compared the cases for each specific substance to the 
general dependence controls. We found that the G allele of rs1799971 was consistently 
protective (odds ratio of 0.83 to 0.93) across all five substances (Table 3), consistent with the 
interpretation that this allele is a non-substance-specific protective factor. 
To further confirm robustness, we examined the effect of redefining general dependence using 
alternative definitions for nicotine dependence, namely the Fagerström Test for Nicotine 
Dependence (FTND) (case ≥ 4, control ≤ 1; 13 studies, N = 8,481) or DSM-IV nicotine 
dependence (14 studies, N = 11,711), in place of our CPD-based heavy/light phenotype (20 
studies, N = 16,908). Analyses of these smaller samples gave similar protective odds ratios for 
general dependence, though results were not statistically significant: OR = 0.91, 95% C.I. (0.81-
1.02) for FTND and OR = 0.94, 95% C.I. (0.85-1.03) for DSM-IV nicotine dependence.  
3.2. For each substance-specific dependence, the G allele of rs1799971 is similarly 
protective but non-significant 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
15 
 
In our primary test of rs1799971 genotype as the dependent variable on the 9 datasets that had 
assessed all five substance dependence diagnoses and exposures, we obtained odds ratios that 
ranged from 0.89 (nicotine dependence) to 0.92 (cocaine dependence). The odds ratio for each 
specific substance showed the same protective direction as that for general substance 
dependence, though none was statistically significant in these smaller samples (Table 4). Also, 
odds ratios for specific substances did not differ significantly from each other (Table S2), 
suggesting consistency across substances. 
We also examined traditional logistic regression in these 9 datasets. Each substance dependence 
diagnosis was examined as the outcome (cases dependent on that substance and controls required 
to be non-dependent but exposed to that substance), with rs1799971 as the predictor and the 
remaining diagnoses as covariates. Results were similar to those from our ordinal logistic model 
(Table 4, bottom half). Finally, analyzing all available datasets for these same case/control 
outcomes (cases dependent on each specific substance, controls non-dependent and exposed to 
that substance) also showed protective, but non-significant, odds ratios consistent with those seen 
in the datasets that assessed all dependence diagnoses and exposures (Supplementary Figures S1-
S5).  
4. DISCUSSION 
This project, the first collaborative genetic meta-analysis to investigate specific and general 
liability for these substance dependence diagnoses, has demonstrated that the G allele of 
rs1799971 has a modest protective effect on general substance dependence liability (OR = 0.90, 
95% C.I. (0.83-0.97), p-value = 9.52 × 10−3) in samples of European ancestry. This is the first 
meta-analysis to show that this non-synonymous variant, which has been heavily studied for 
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functional effects, is significantly associated in European ancestry samples with liability to 
substance dependence. The small but significant effect size of rs1799971 suggests that variability 
in previous association reports may be due in part to sampling variation. This collaborative meta-
analysis benefited from the opportunity to define uniform phenotypes across studies, perform 
coordinated, de novo analyses to test our hypotheses, and include existing datasets that have not 
yet focused on the question of rs1799971 and addiction.  
The protective effect of this allele on substance dependence liability appears to be non-specific: 
it is not driven primarily by dependence on any particular substance. For each substance-specific 
subset of cases compared to the general dependence controls, we observed a protective effect of 
similar size to that observed for general dependence. Additional substance-specific analyses 
similarly showed consistent protective effects of the G allele. These substance-specific odds 
ratios were not statistically significant, but this may have been largely due to reduced sample size 
and power. 
These findings indicate that rs1799971 in OPRM1 may contribute to mechanisms of addiction 
liability that are shared across different addictive substances, consistent with the high genetic 
correlation between the traits, high co-morbidity, and with prior studies showing that both 
substance-specific and non-specific genetic effects on addiction liability can be expected (Bierut 
et al. 1998;  Kendler et al. 2007;  Merikangas et al. 1998;  Swan et al. 1997;  Tsuang et al. 1998;  
Vanyukov et al. 2012;  Vanyukov et al. 2003). Rs1799971 is now one of the few examples of a 
genetic factor that demonstrates a similar, general effect across multiple substances, albeit of 
modest magnitude. In this sense, our study is similar to a genome-wide association study of 
multiple psychiatric disorders that identified variants having a common, cross-disorder genetic 
effect on five major psychiatric diseases (Cross-Disorder Group of the Psychiatric Genomics 
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Consortium 2013). Both studies underscore the value of investigating the genetics of general 
liability underlying related diseases. Genetic studies of addiction would therefore benefit from 
including measures pertaining to multiple substances that can then be analyzed collectively. 
Indeed, a very recent genome-wide study of general substance dependence liability using four of 
the five substances studied here (alcohol, cannabis, cocaine, opioids) reported novel associations 
(Wetherill et al. 2015), further supporting the potential benefits.  
Our results are compatible with negative results from prior genome-wide meta-analyses of 
cigarettes-per-day (Liu et al. 2010;  The Tobacco and Genetics Consortium 2010;  Thorgeirsson 
et al. 2010). Our hypothesis-driven analyses of a single SNP translate to a study-wide required 
significance threshold of 9.76x10-3. This led to statistically significant evidence for a modest 
effect (OR=0.90) of rs1799971 on general substance dependence liability, in N=16,908 subjects 
(Table 3). The three genome-wide smoking consortia tested OPRM1 only in each consortium 
separately (N=38,000, N=31,000, and N=16,000 smokers with cigarettes-per-day); estimated 
power to have detected the nicotine-specific odds ratio of 0.93 (Table 3) in at least one of the 
three consortia with genome-wide significance (alpha=5x10-8) is only 4%. Power details are in 
Supplementary Text S2. Hence it is not surprising that these smoking consortia did not report an 
OPRM1 effect.  
This study contributes valuable information to connect functional findings to the clinically 
important outcome of addiction in humans. Several neurobiological, functional, and 
physiological changes have been demonstrated for the rs1799971 (A118G) amino acid change 
and a corresponding mutation in a similar region of the receptor in mice (A112G) (Drakenberg et 
al. 2006;  Huang et al. 2012;  Mague and Blendy 2010;  Palmer and de Wit 2012;  Ray et al. 
2012;  Wang et al. 2014). In vitro studies of the G allele have reported increased binding to β-
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endorphin (Bond et al. 1998), altered downstream signaling (Deb et al. 2010), and decreased mu 
opioid receptor expression (Zhang et al. 2005). In human brain imaging, the G allele is 
associated with striatal dopamine response to alcohol (Ramchandani et al. 2011) and increased 
mu opioid receptor binding potential (Ray et al. 2011). In mouse knock-in models (A112G), the 
G/G knock-in has shown reduced receptor protein levels overall and reduced reinforcing value of 
morphine in female mice (Mague et al. 2009), reduced G-protein signaling (Wang et al. 2014), 
and increased peak dopamine response to alcohol challenge (Ramchandani et al. 2011); changes 
are often brain-region specific.   
It is important to note that some functional and neurobiological findings have been interpreted as 
indicating that the G allele of rs1799971 should increase risk for addiction, for example due to its 
association with greater alcohol-induced reinforcement and reward (Ramchandani et al. 2011;  
Ray and Hutchison 2004;  Ray and Hutchison 2007;  Ray et al. 2010). Our data-driven evidence 
of a modest protective effect of this allele on substance dependence liability is thus surprising 
and all the more important to integrate with functional findings to understand downstream 
contributions to human substance dependence. A protective effect of the G allele on addiction 
may be consistent with either increased or decreased reward/reinforcement, for example due to 
varying roles of positive versus negative reinforcement at different stages in the transition from 
use to dependence. Modeling these connections remains an open area to be worked out by 
neurobiological theories of addiction (Ray et al. 2012).  
This project demonstrates the value of collaborative data sharing and meta-analysis, as the 
modest odds ratio of rs1799971 would be challenging to detect and consistently replicate in 
modestly sized candidate gene studies (Hall et al. 2013;  Hart et al. 2013). Also important was 
our approach of defining consistent phenotypes across all datasets. In particular, careful 
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definition of controls can help to detect associations (Nelson et al. 2013;  Schinka et al. 2002). In 
our case, requiring controls to be at least 25 years of age led to stronger association results even 
with the reduced the number of controls.  
This study has limitations. First, as in any meta-analysis, sample heterogeneity could not be 
completely avoided. Studies had diverse ascertainment schemes, with some designed to recruit 
dependent cases for one particular substance. Some studies recruited from the general population 
while others recruited potentially more extreme cases from treatment centers. Hence, over- and 
under-representation of phenotypes were present in contributing datasets, and the severity of 
dependence, degree of co-morbid dependence, and prevalence of substance exposure varied. 
Reduced proportions of exposed controls would reduce effective sample size and power for a 
study. But overall, uniform phenotype definitions were an important design feature to ameliorate 
effects of heterogeneity.  Although some bias may have occurred, it seems unlikely to have been 
systematic in either direction. Similarly, it seems unlikely that systematic bias would have 
occurred due to differences between studies that contributed to this meta-analysis and those that 
declined to participate. 
Second, this project interrogated only the non-synonymous variant rs1799971. As with any 
statistical association, our finding may reflect a proxy association for which the true functional 
variant(s) remain to be recognized. Other OPRM1 variants have been associated with addiction 
and merit consideration for future study (Clarke et al. 2013;  Hancock et al. 2015;  Zhang et al. 
2006a). Analyses of multiple SNPs and haplotypes will also be of future interest: recent evidence 
indicates an important role in heroin addiction for the haplotype structure of OPRM1, with the A 
allele of rs1799971 showing association only in the presence of the C allele of rs3778150 
(Hancock et al. 2015). Importantly, (Hancock et al. 2015) also found that the G allele of 
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rs1799971 is protective (A allele confers risk) on that background, agreeing with the direction of 
effect observed in our meta-analysis of general substance dependence.  
Third, further phenotypic refinement is possible. We did not consider substance abuse criteria, 
nor did we use the newer diagnostic system, DSM-5 (American Psychiatric Association 2013). 
Our threshold for exposure was a single use for all substances except nicotine; therefore, the 
genetic effect of rs1799971 detected by our analyses may involve a combination of effects on 
development of regular/repeated use and effects on dependence. We focused on dichotomous 
diagnoses for each substance. For nicotine, we examined heavy/light smoking as the most widely 
available nicotine trait in our datasets. Consistency of results was confirmed using DSM-IV and 
Fagerström Test of Nicotine Dependence criteria when available.  Because we focused on 
dichotomous diagnoses that could then be combined into the general substance dependence 
diagnosis, we did not examine quantitative or categorical cigarettes-per-day.  
Fourth, we focused on main effects of rs1799971 to limit multiple testing. Thus, we did not 
examine gene-environment interactions (e.g., sex-specific effects) or gene-gene interactions. We 
did adjust statistically for sex, which showed no evidence for a main effect on general substance 
dependence (p = 0.57).  Interactions likely have roles in a complex trait such as addiction, and 
could attenuate the genetic main effect when not accounted for (e.g. when the effect occurs only 
in a specific stratum). Thus, it is possible that the modest main effect that we detected could 
translate to a stronger effect if particular genetic or environmental backgrounds are considered.  
Future work could examine interactions nominated in the literature (Mague et al. 2009;  Miranda 
et al. 2013;  Ray et al. 2006).  
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Finally, a model that explicitly partitions the association between a general factor for any 
substance dependence and substance-specific components was not fitted to these data. Although 
such a model would allow a more refined distinction between general and specific associations 
(Medland and Neale 2010;  Neale et al. 2006), we chose not to apply this because of the 
complexities of running and integrating such analyses across sites.  
In closing, this data-driven, collaborative meta-analysis has demonstrated a modest protective 
effect of the G allele of rs1799971 on general liability to substance dependence. This work 
highlights the benefits of jointly studying related disorders: larger samples and insight into 
factors involved in underlying shared liability. An important strength of our approach is that the 
analyses of our datasets were designed and conducted in collaboration with the originating 
investigators. Thus, we benefited from collaborators' deep knowledge of their own data and our 
combined expertise on addiction. This effort underscores the value of collaboratively sharing 
data and expertise to accelerate discoveries. 
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Figure 1. Forest plot of general substance dependence and rs1799971 across studies that had at least 
5 cases and 5 controls. Summary odds ratio, 95% Confidence Interval, and p-values are based on 
fixed effect meta-analysis. *indicates the subset of 10 studies that had all five specific substance 
dependence diagnoses, examined in secondary analyses to confirm consistency of results. Estimated 
heterogeneity variance was Q = 20.13 with a p-value of 0.387 among all 20 studies and Q = 6.49 
with a p-value of 0.69 among the subset of 10 studies. 
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Table 1: Study descriptions: sample sizes, G (minor) allele frequencies (overall, in general 
dependence cases, in general dependence controls), proportions of male participants, and age 
distribution (minimum, first quartile, median, third quartile, and maximum) of each study. 
Study 
Total 
N 
G-allele-
freq 
Case 
G-
allele-
freq 
Control 
G-
allele-
freq 
proport-
male 
age 
min age_q1 age_med age_q3 age_max 
BG a  3999 0.14 0.13 0.17 0.83 18 25 28 30 58 
CADD b  409 0.13 0.12 0.18 0.56 12 21 28 47 72 
CATS c  1748 0.12 0.12 0.13 0.57 18 29 36 43 65 
CEDAR-SADS d  747 0.12 0.12 0.12 0.35 14 18 37 42 65 
Cinciripini e  627 0.11 0.09 0.15 0.48 18 33 42 50 74 
COGA f  1024 0.12 0.11 0.13 0.46 18 36 43 51 77 
COGEND g  2024 0.13 0.13 0.15 0.61 25 32 37 41 65 
Finnish Health 2000 h  1025 0.21 
0.20 0.22 
0.8 30 37 46 54 87 
FSCD i  558 0.13 0.13 0.10 0.5 18 25 34 40 54 
FT12 j  617 0.22   0.48 20 22 22 23 27 
GADD k  281 0.12 0.13 0.15 0.57 12 15 16 19 61 
GESGA l  3501 0.12 0.11 0.11 0.65 18 39 47 56 84 
Kreek m  750 0.11 0.10 0.13 0.59 17 31 43 52 82 
MCTFR-Parents n  3842 0.11 0.10 0.11 0.46 30 43 46 50 72 
NAG-AUS o  1281 0.12 0.12 0.12 0.59 18 36 43 50 82 
NAG-FIN p  879 0.21   0.7 42 52 55 58 77 
NYS q  552 0.1 0.07 0.10 0.49 35 37 39 41 44 
OYSUP r  357 0.13   0.5 20 21 21 21 23 
PAGES s  409 0.11   0.68 17 27 37 45 68 
PiP t  809 0.11 0.11 0.15 0.48 18 35 43 53 79 
ROMA u  732 0.21 0.16 0.38 0.83 18 25 28 32 53 
SMOFAM v  166 0.12 0.18 0.12 0.63 26 27 29 30 62 
Utah w  463 0.13 0.12 0.14 0.59 25 54 61 67 86 
VA-Twin x  672 0.12 0.15 0.10 0.32 21 30 38 46 58 
Yale-Penn y  1217 0.12   0.41 16 30 39 46 72 
Total 28689 
(0.10-
0.22) 
  (0.32-
0.83) (12-42) (15-54) (16-61) (19-67) (23-87) 
References: a (Nikolov et al. 2011); b (Stallings et al. 2005;  Stallings et al. 2003); c (Nelson et al. 2014;  Nelson et al. 2013); d 
(Maher et al. 2011); e (Carter et al. 2008;  Cinciripini et al. 2006;  Cinciripini et al. 2005;  Lam et al. 2012;  Minnix et al. 2011;  
Robinson et al. 2007;  Robinson et al. 2011); f (Edenberg 2002;  Edenberg et al. 2010); g (Saccone et al. 2009a;  Saccone et al. 
2009b); h (Aromaa and Koskinen 2004;  Rouvinen-Lagerstrom et al. 2013); i (Bierut et al. 2010;  Bierut et al. 2008); j (Broms et al. 
2012;  Kaprio et al. 2002); k (Kamens et al. 2013); l (Frank et al. 2012;  Treutlein et al. 2009); m (Levran et al. 2008); n (Iacono et al. 
1999;  Keyes et al. 2009;  McGue et al. 2007;  Miller et al. 2012); o (Loukola et al. 2008;  Saccone et al. 2007); p (Loukola et al. 
2008); q (Elliott et al. 1985;  Elliott et al. 1989;  Hoft et al. 2009); r (Andrews et al. 2003); s (Van den Oord et al. 2006); t (David et 
al. 2011); u (Nikolov et al. 2011); v (Hops et al. 2000); w (Weiss et al. 2008); x (Chen et al. 2009;  Kendler et al. 2007;  Zhang et al. 
2006b); y (Gelernter et al. 2014;  Gelernter et al. 2013a;  Gelernter et al. 2013b) 
Tables 1-4
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Table 2. Numbers of cases, total controls, and controls with exposure to each substance.  These numbers were based on a filtered 
sample that removed participants not exposed to alcohol, and participants who are less than 25 years of age and have with no 
dependence to any assessed substances. NA indicates that the substance was not assessed in the study. 
 
Alcohol Cigarettes Per Day (CPD) Cannabis Cocaine Opioid 
General Substance 
Dependence 
Datasets Cases 
Total 
Controls 
Heavy 
Smokers 
Total 
Controls 
Exposed 
Controls 
Cases 
Total 
Controls 
Exposed 
Controls 
Cases 
Total 
Controls 
Exposed 
Controls 
Cases 
Total 
Controls 
Exposed 
Controls 
Cases Controls 
BG 277 1278 1449 4 4 NA NA NA NA NA NA NA NA NA 948 3 
CADD 93 264 54 109 57 72 285 218 35 306 141 6 351 106 161 72 
CATS 651 1032 NA NA NA 857 831 765 416 1272 875 1259 429 102 1444 209 
CEDAR-SADS 179 562 NA NA NA 255 486 338 86 655 263 114 627 418 342 399 
Cinciripini NA NA 253 34 NA NA NA NA NA NA NA NA NA NA 253 34 
COGA 612 410 242 483 140 196 823 475 224 795 204 86 933 193 648 318 
COGEND 463 1529 584 935 923 192 1808 1543 132 1871 560 34 1970 191 918 734 
Finnish Health 
2000 
417 512 89 463 180 3 1011 0 0 1014 0 2 1012 0 453 283 
FSCD 280 230 124 276 58 170 340 213 237 273 55 81 429 100 309 193 
FT12 93 470 198 15 15 NA NA NA NA NA NA NA NA NA 251 0 
GADD 43 110 11 57 NA 45 108 78 9 144 29 NA 153 35 75 20 
GESGA 1333 1933 NA NA NA NA NA NA NA NA NA NA NA NA 1280 1926 
Kreek 42 684 NA NA NA NA NA NA 82 644 41 528 198 NA 527 198 
MCTFR-Parents 226 2504 NA NA NA 93 2637 1637 37 2695 452 12 2722 125 283 2442 
NAG-AUS 359 972 737 594 102 79 1249 694 5 1322 74 17 1310 137 766 507 
NAG-FIN 221 513 354 115 115 NA NA NA NA NA NA NA NA NA 450 101 
NYS 65 466 71 135 63 25 508 368 26 507 157 1 532 86 135 125 
OYSUP All participants were under 25 years of age 
PAGES 64 335 132 83 40 77 320 160 7 391 67 8 390 30 210 61 
PiP NA NA 347 54 NA NA NA NA NA NA NA NA NA NA 332 52 
ROMA 18 240 209 7 6 NA NA NA NA NA NA NA NA NA 177 4 
SMOFAM NA NA 20 67 34 NA NA NA NA NA NA NA NA NA 20 67 
Utah 112 283 235 60 60 36 359 88 16 379 34 9 386 9 272 35 
VA-Twin NA NA 193 70 NA NA NA NA NA NA NA NA NA NA 186 68 
Yale-Penn 799 208 1094 113 NA 397 566 500 911 259 167 703 478 214 1208 3 
Total 6347 14535 6396 3674 1797 2497 11331 7077 2223 12527 3119 2860 11920 1746 11648 7834 
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Table 3. Summary of the effect of rs1799971 on general substance dependence. 
Model Cases Controls Cochrane’s Q Q-Pvalue Odds Ratio L95%-U95% OR-Pvalue 
Gen-Dep = age sex rs1799971 9064 7844 20.13 0.387 0.90 0.83-0.97 0.952 
Alcohol = age sex rs1799971 5086 7623 12.08 0.672 0.92 0.83-1.01 0.696 
Nicotine = age sex rs1799971 3358 2670 16.84 0.265 0.93 0.83-1.05 0.244 
Cannabis = age sex rs1799971 2077 5115 7.63 0.746 0.83 0.71-0.98 0.279 
Cocaine = age sex rs1799971 1307 5313 7.68 0.809 0.87 0.73-1.04 0.132 
Opioid = age sex rs1799971 2139 5168 7.87 0.641 0.84 0.70-1.00 0.557 
Model column shows what outcome phenotype was tested for each model. Gen-Dep denotes general substance dependence. Each 
substance denotes the subsets of general substance dependence that were tested in interpretative phase of the analysis. All effects 
shows are fixed effect estimates. Controls were filtered for age and exposure to alcohol. 
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Table 4. Summary of the effect of rs1799971 on specific substance dependence diagnoses in 9 studies that assessed all five substance 
dependence diagnoses and exposures. 
Ordinal Logistic Regression Results 
Substance Cases Controls Cochrane’s Q Q-Pvalue Odds Ratio L95%-U95% OR-Pvalue 
Alcohol 2031 3361 8.90 0.351 0.90 0.76-1.06 0.218 
Nicotine 2718 2674 7.78 0.455 0.89 0.74-1.07 0.216 
Cannabis 839 4553 10.76 0.216 0.91 0.73-1.14 0.420 
Cocaine 992 4085 0.86 0.990 0.92 0.69-1.24 0.593 
Opioid 607 4274 3.12 0.682 0.91 0.65-1.27 0.577 
Traditional Logistic Regression Results (Dependence as outcome variable) 
Alcohol 2051 3430 10.66 0.222 0.88 0.76-1.02 0.974 
Nicotine 2066 1412 8.69 0.276 0.91 0.76-1.08 0.267 
Cannabis 861 3036 9.08 0.336 0.90 0.74-1.09 0.283 
Cocaine 1011 899 0.85 0.997 0.91 0.70-1.19 0.492 
Opioid 600 577 2.31 0.679 0.91 0.67-1.24 0.547 
Substance column shows the tested outcome phenotype. All effects shows are fixed effect estimates. In the traditional logistic 
regression results, controls were required to be exposed each tested substance, in addition to meeting the previously applied filters for 
age and exposure to alcohol.  
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Supplementary Text S1: Dataset Descriptions. 
GENETIC EPIDEMIOLOGY OF OPIOID DEPENDENCE IN BULGARIA  
(BG / GEODBG) [1] 
GEODBG is a collaboration of sites in the United States and in Bulgaria. Subjects were recruited 
from major Bulgarian cities, primarily Sofia and Plovdiv. Participants had at least 1 year history 
of daily heroin use. 
The MAGIC was used to obtain DSM-IV lifetime diagnoses for abuse/dependence for alcohol, 
heroin and other illicit drugs. Nicotine consumption measures were also collected. 
For this meta-analysis, GEODBG contributed rs1799971 genotypes from 2,098 unrelated ethnic 
Bulgarians heroin dependent and 1,901 ethnic Bulgarian population controls (BG dataset); and 
from 424 heroin dependent Bulgarian Romas and 308 Roma population controls (ROMA 
dataset). The study obtained informed consent from participants and approval from the 
appropriate institutional review boards at Washington University and Sofia Medical University. 
DNA was extracted from venous blood samples from each heroin dependent subject, and from 
10mm punches (PKU Guthrie cards) for controls, using chemagic Magnetic Separation Module I 
(chemagen AG) according to manufacturer’s protocol. A Biomek FX robot was used for DNA 
aliquoting in 384 well plates and TaqMan assays for genotyping the 118A>G polymorphism on a 
7900HT Fast Real-Time PCR System (both from Applied Biosystems). SDS v2.2.2 analysis 
software tool was used for base-calling and visualization of the genotype data. For quality 
control purposes, four samples from each plate were re-genotyped on another plates (no errors 
were detected). The call rate for the five case and the four control 384 plates was over 95%. 
FAMILY, TWIN, AND ADOPTION STUDIES OF THE COLORADO CENTER ON 
ANTISOCIAL DRUG DEPENDENCE (CADD) [2-3] 
The Colorado Center on Antisocial Drug Dependence (CADD) sample encompasses over 5000 
individuals that have been studied in a longitudinal design to gain a better understanding of the 
genetic mechanisms of adolescent drug abuse.  The full CADD sample consists of both clinical 
and community populations [2-3].  The subjects used in the current analyses were from the 
Colorado Adolescent Substance Abuse (ASA) family study.  Clinical probands were recruited 
from three treatment facilities in the Denver metropolitan area.  The probands were 13-19 years 
of age at time of assessment and were drawn from individuals with consecutive admissions to the 
treatment facilities between February 1993 and June 2001.  Community probands were matched 
to the clinical probands based on age, gender, ethnicity and zip code. At the time of assessment 
all individuals living in the same household as the proband were interviewed.  All study 
participants were given cognitive, psychiatric, and socio-demographic assessments that included 
both structured diagnostic interviews as well as self-reported questionnaires.  Since the samples 
were drawn from a study of related individuals SAS (proc surveyselect) was used to randomly 
select one individual per family for inclusion in the current analysis.  Substance use patterns 
were assessed with the Composite International Diagnostic Interview—Substance Abuse Module 
(CIDI-SAM), a structured, face-to-face diagnostic assessment designed to be administered by 
trained, lay interviewers [4]. This assessment procedure has been shown to be valid for 
adolescent subjects [5].  From the CIDI-SAM the alcohol, cocaine, nicotine, opioid and cannabis 
Supplementary Text S1
Click here to download Supplementary Material: oprm1-suppl_text_S1_2015-07-17final.docx 
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DSM-IV dependence were examined.  Additionally the number of cigarettes smoked per day at 
the time of maximum smoking was also analyzed. All research was approved by the institutional 
review board of the University of Colorado. Genomic DNA was isolated from buccal cells using 
a modification of published procedures [6-8]. Taqman assays for allelic discrimination (Applied 
Biosystems, Foster City, CA) were used to determine SNP genotypes. QC included the removal 
of individuals with fewer than 90% genotypes across all SNPs tested in these individuals 
(assumed poor quality DNA sample). Genotypes were called by two independent individuals and 
removed in case of a disagreement. 
COMORBIDITY AND TRAUMA STUDY (CATS) [9-10] 
The Comorbidity and Trauma Study (CATS), a collaboration of investigators at Washington 
University School of Medicine, Queensland Institute of Medical Research, and National Drug 
and Alcohol Research Centre of the University of New South Wales, is a case-control genetic 
association study of heroin dependence. Heroin dependent cases were recruited from opioid 
replacement therapy clinics in the greater Sydney region. Controls with little or no lifetime 
history of recreational opioid use were recruited from economically-disadvantaged 
neighborhoods in geographic proximity to the clinics. 
Psychiatric diagnostic interviews modified from the Semi-Structured Assessment for the 
Genetics of Alcoholism were completed in-person and included sections on illicit drug and 
alcohol dependence from which exposure information and DSM-IV lifetime diagnoses of opioid, 
cannabis, sedative, stimulant, cocaine, and alcohol abuse and dependence were obtained. CATS 
contributed a sample of 1259 heroin dependent cases and 429 controls for this meta-analysis. All 
participants, unrelated individuals of European ancestry who were successfully genotyped for 
rs1799971, had provided informed consent. Institutional review board approval was obtained 
from the three primary institutions and the area health service ethics committees governing 
participating clinics.  
DNA was extracted from whole blood samples. Genotyping was performed on an Illumina 
BeadStation using GoldenGate technology. Details of data cleaning have been reported 
previously [9-10]. In brief, SNPs were excluded due to genotyping failure, call rate less than 
95%, minor allele frequency less than 2%, and Hardy-Weinberg deviations.  Data from samples 
were excluded due to phenotypic-genotypic gender mismatch, duplication due to participation in 
the project multiple times, and cryptic relatedness with identity by descent greater than 0.5. 
Principal components analyses conducted using the smartpca program in the Eigensoft 3.0 
package [11] facilitated removal of individuals from the sample who were not of European 
ancestry.  
CENTER FOR EDUCATION AND DRUG ABUSE RESEARCH (CEDAR) – 
SUBSTANCE ABUSE AND THE DOPAMINE SYSTEM STUDY (SADS) [12] 
CEDAR and SADS are United States projects. Participants were recruited from the Pittsburgh 
metropolitan area through newspaper advertisements, social service agencies, substance abuse 
treatment programs and various other media. 
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For this project, analyses were conducted on a combined sample of from two studies with 
distinct but related ascertainment schemes, from the same Greater Pittsburgh population, joined 
in the Substance Use Disorder Liability: Candidate System Genes study (R01 DA019157). 
CEDAR (P50 DA005605) is a longitudinal family/high-risk study of substance use disorder 
(SUD) [12]. Both CEDAR and SADS studies focus on general (non-drug-specific) liability to 
SUD [13-14]. Parents from a sample of nuclear families, ascertained in CEDAR through the 
father who did or did not have a DSM-III-R SUD (DSM-IV was introduced after this study 
started) related to illicit drugs (an illegal substance or nonmedical use of a prescribed 
psychoactive drug), provided a source for male and female cases and controls. An expanded 
version of the Structured Clinical Interview for DSM-III-R-outpatient version (SCID-OP) [15] 
was administered by experienced research associates to obtain psychiatric diagnoses for adults in 
CEDAR. All diagnoses have been revised using DSM-IV criteria, and the SADS participants 
were diagnosed accordingly. To evaluate smoking behavior, Fagerström Test for Nicotine 
Dependence (FTND) was administered. Control subjects had no substance (including alcohol) 
use disorder, or Axis I or II psychiatric disorder. Probands in the SADS study (R01 DA011922) 
were males 12-18 years of age having a DSM-IV diagnosis of substance dependence related to 
use of illicit drugs. In both CEDAR and SADS subsamples, probands having a psychiatric 
disorder other than SUD qualified for the study unless they had a lifetime history of psychosis or 
any other condition where valid reporting was uncertain. The vocabulary subscale of WISC-III 
(subjects below age 16) or WAIS-III (age 16 and older) was administered prior to 
implementation of the protocol and was required to be in the normal range (>70). Since 
psychiatric comorbidity is common among substance abusers, cases were not excluded for any 
Axis I or Axis II disorders. The CEDAR and SADS subjects were self-identified European-
Americans from the same Greater Pittsburgh geographic area, and the genomic inflation factor 
based on all genotyped SNPs, evaluating the excess false-positive rate, was satisfactory at .9812. 
For this meta-analysis, CEDAR contributed a sample of 757 unrelated European-Americans who 
were genotyped for rs1799971. The study obtained informed consent from participants and 
approval from the University of Pittsburgh Institutional Review Board. 
DNA was extracted from whole blood.  Genotyping of the DNA samples was carried out using 
the Illumina BeadArray platform in a custom 1536 SNP oligonucleotide pool assay covering 106 
genes representing major neurobiological systems (candidate system genes).  The procedures 
involved and quality control are described previously [12] and in the online Appendix to that 
article. Individuals missing > 20% of genotype data and then SNPs with 5% missing rates were 
dropped from the dataset.  
CINCIRIPINI OPRM1 [16-22] 
1.1 CASSI 
Participants for CASSI were recruited from the University of Texas MD Anderson Cancer 
Center through community-based telephone screening to determine eligibility for the study. The 
participants were treatment-seeking adult smokers who were enrolled in a study to evaluate the 
efficacy of a handheld computer-assisted gradual smoking reduction treatment. 
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The presence of Nicotine Dependence disorder was assessed using self-reported DSM-IV 
criteria. Additionally, nicotine dependence severity was estimated using the Fagerström Test for 
Nicotine Dependence (FTND) and self-reported cigarettes smoked per day (CPD). 
For this meta-analysis, CASSI contributed an unrelated sample of 112 African-American and 
408 European-Americans who were genotyped for rs1799971. The study obtained informed 
consent from participants and approval from the MD Anderson institutional review board. 
1.2 Genomic DNA was extracted from buccal cells by using the QIAmp DNA kit (cat. # 
51185; QIAGEN Sciences,Valencia, CA). Single nucleotide polymorphism genotyping of the 
DA and nAChR SNPs was performed using the 5’ nuclease assay to discriminate between the 
two alleles representing the different genotypes. The assay reagents for SNP genotyping 
consisted of a mix of PCR primers and probes. OPRM1 (Probe 1: FAM- 
CTTAGATGGCGACCTGT; Probe 2: VIC-CTTAGATGGCAACCTGT; Primer 1: 
CGGTTCCTGGGTCAACTTGTC; Primer 2: GTTCGGACCGCATGGGT) polymorphism was 
genotyped in assay-by-design. Each assay enables scoring of both alleles in a single well within a 
384-well plate. All assays are optimized to work with genomic DNA and TaqMan Universal 
Master Mix. Forty cycles of PCR were performed and analyzed using an ABI Prism 7900HT 
Sequence Detection System from Applied Biosystems. 
1.3 SCOPE 
Participants for SCOPE were recruited from the University of Texas MD Anderson Cancer 
Center through community-based telephone screening to determine eligibility for the study. The 
participants were treatment-seeking adult smokers who were enrolled in a study to assess the 
efficacy of venlafaxine as a smoking cessation pharmacotherapy [18]. 
The presence of Nicotine Dependence disorder was assessed using self-reported DSM-IV 
criteria. Additionally, nicotine dependence severity was estimated using the Fagerström Test for 
Nicotine Dependence (FTND) and self-reported cigarettes smoked per day (CPD). 
For this meta-analysis, SCOPE contributed an unrelated sample of 6 African-American and 116 
European-Americans who were genotyped for rs1799971. The study obtained informed consent 
from participants and approval from the MD Anderson institutional review board. 
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1.4 Genomic DNA was extracted from buccal cells by using the QIAmp DNA kit (cat. # 
51185; QIAGEN Sciences,Valencia, CA). Single nucleotide polymorphism genotyping of the 
DA and nAChR SNPs was performed using the 5’ nuclease assay to discriminate between the 
two alleles representing the different genotypes. The assay reagents for SNP genotyping 
consisted of a mix of PCR primers and probes. OPRM1 (Probe 1: FAM- 
CTTAGATGGCGACCTGT; Probe 2: VIC-CTTAGATGGCAACCTGT; Primer 1: 
CGGTTCCTGGGTCAACTTGTC; Primer 2: GTTCGGACCGCATGGGT) polymorphism was 
genotyped in assay-by-design. Each assay enables scoring of both alleles in a single well within a 
384-well plate. All assays are optimized to work with genomic DNA and TaqMan Universal 
Master Mix. Forty cycles of PCR were performed and analyzed using an ABI Prism 7900HT 
Sequence Detection System from Applied Biosystems. 
1.5 PEERS EMA 
Participants for PEERS EMA were recruited from the University of Texas MD Anderson Cancer 
Center through community-based telephone screening to determine eligibility for the study. The 
participants were non-treatment-seeking adult smokers who were enrolled in a study to assess 
real-time cigarette craving and mood before and after smoking [16]. 
The presence of Nicotine Dependence disorder was assessed using self-reported DSM-IV 
criteria. Additionally, nicotine dependence severity was estimated using the Fagerström Test for 
Nicotine Dependence (FTND) and self-reported cigarettes smoked per day (CPD). 
For this meta-analysis, PEERS EMA contributed an unrelated sample of 42 African-American 
and 26 European-Americans who were genotyped for rs1799971. The study obtained informed 
consent from participants and approval from the MD Anderson institutional review board. 
1.6 Genomic DNA was extracted from buccal cells by using the QIAmp DNA kit (cat. # 
51185; QIAGEN Sciences,Valencia, CA). Single nucleotide polymorphism genotyping of the 
DA and nAChR SNPs was performed using the 5’ nuclease assay to discriminate between the 
two alleles representing the different genotypes. The assay reagents for SNP genotyping 
consisted of a mix of PCR primers and probes. OPRM1 (Probe 1: FAM- 
CTTAGATGGCGACCTGT; Probe 2: VIC-CTTAGATGGCAACCTGT; Primer 1: 
CGGTTCCTGGGTCAACTTGTC; Primer 2: GTTCGGACCGCATGGGT) polymorphism was 
genotyped in assay-by-design. Each assay enables scoring of both alleles in a single well within a 
384-well plate. All assays are optimized to work with genomic DNA and TaqMan Universal 
Master Mix. Forty cycles of PCR were performed and analyzed using an ABI Prism 7900HT 
Sequence Detection System from Applied Biosystems. 
1.7 PEERS NS 
Participants for PEERS NS were recruited from the University of Texas MD Anderson Cancer 
Center through community-based telephone screening to determine eligibility for the study. The 
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participants were non-treatment-seeking adult smokers who were enrolled in a study to assess 
psychophysiological response to nicotine nasal spray [17, 20-21]. 
The presence of Nicotine Dependence disorder was assessed using self-reported DSM-IV 
criteria. Additionally, nicotine dependence severity was estimated using the Fagerström Test for 
Nicotine Dependence (FTND) and self-reported cigarettes smoked per day (CPD). 
For this meta-analysis, PEERS NS contributed an unrelated sample of 40 African-American and 
32 European-Americans who were genotyped for rs1799971. The study obtained informed 
consent from participants and approval from the MD Anderson institutional review board. 
1.8 Genomic DNA was extracted from buccal cells by using the QIAmp DNA kit (cat. # 
51185; QIAGEN Sciences,Valencia, CA). Single nucleotide polymorphism genotyping of the 
DA and nAChR SNPs was performed using the 5’ nuclease assay to discriminate between the 
two alleles representing the different genotypes. The assay reagents for SNP genotyping 
consisted of a mix of PCR primers and probes. OPRM1 (Probe 1: FAM- 
CTTAGATGGCGACCTGT; Probe 2: VIC-CTTAGATGGCAACCTGT; Primer 1: 
CGGTTCCTGGGTCAACTTGTC; Primer 2: GTTCGGACCGCATGGGT) polymorphism was 
genotyped in assay-by-design. Each assay enables scoring of both alleles in a single well within a 
384-well plate. All assays are optimized to work with genomic DNA and TaqMan Universal 
Master Mix. Forty cycles of PCR were performed and analyzed using an ABI Prism 7900HT 
Sequence Detection System from Applied Biosystems. 
1.9 PEERS WS 
Participants for PEERS WS were recruited from the University of Texas MD Anderson Cancer 
Center through community-based telephone screening to determine eligibility for the study. The 
participants were treatment-seeking adult smokers who were enrolled in a behavioral smoking 
cessation therapy trial to evaluate the relationship between nicotine withdrawal and post-
cessation affect [19, 22]. 
The presence of Nicotine Dependence disorder was assessed using self-reported DSM-IV 
criteria. Additionally, nicotine dependence severity was estimated using the Fagerström Test for 
Nicotine Dependence (FTND) and self-reported cigarettes smoked per day (CPD). 
For this meta-analysis, PEERS WS contributed an unrelated sample of 23 African-American and 
45 European-Americans who were genotyped for rs1799971. The study obtained informed 
consent from participants and approval from the MD Anderson institutional review board. 
Genomic DNA was extracted from buccal cells by using the QIAmp DNA kit (cat. # 51185; 
QIAGEN Sciences,Valencia, CA). Single nucleotide polymorphism genotyping of the DA and 
nAChR SNPs was performed using the 5’ nuclease assay to discriminate between the two alleles 
representing the different genotypes. The assay reagents for SNP genotyping consisted of a mix 
of PCR primers and probes. OPRM1 (Probe 1: FAM- CTTAGATGGCGACCTGT; Probe 2: 
VIC-CTTAGATGGCAACCTGT; Primer 1: CGGTTCCTGGGTCAACTTGTC; Primer 2: 
GTTCGGACCGCATGGGT) polymorphism was genotyped in assay-by-design. Each assay 
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enables scoring of both alleles in a single well within a 384-well plate. All assays are optimized 
to work with genomic DNA and TaqMan Universal Master Mix. Forty cycles of PCR were 
performed and analyzed using an ABI Prism 7900HT Sequence Detection System from Applied 
Biosystems. 
COLLABORATIVE STUDY ON THE GENETICS OF ALCOHOLISM (COGA) [23-24] 
The Collaborative Study on the Genetics of Alcoholism (COGA) is a large, ongoing family-
based study that includes subjects recruited by seven sites around the US: Indiana University, 
State University of New York Health Science Center Brooklyn, University of Connecticut, 
University of Iowa, University of California San Diego, Washington University St Louis, and 
Howard University [23]. Probands were recruited from alcoholism treatment facilities, and after 
obtaining informed consent, additional family members were also contacted. Comparison 
families were recruited from the same communities by a variety of methods. The institutional 
review boards of all participating institutions approved the study. Assessment involved a detailed 
personal interview developed for this project, the Semi-Structured Assessment for the Genetics 
of Alcoholism [25] (SSAGA), which gathers detailed information on alcoholism related 
symptoms along with other drugs and psychiatric symptoms, from which lifetime diagnoses 
based on DSM-IV were derived.   
A case-control sample of unrelated subjects was drawn from the COGA dataset[24]. Cases were 
drawn from the families ascertained through alcohol dependent probands; all cases met DSM-IV 
criteria for alcohol dependence. Controls all had consumed alcohol but did not meet a diagnosis 
of alcohol use, abuse, dependence or harmful use by any of 4 diagnostic systems (Feighner, 
DSM-IIIR, DSM-IV, ICD10), nor a diagnosis of abuse or dependence on cannabis, opioids, 
cocaine, sedatives, or stimulants and did not share a known common ancestor with a case[24]. 
DNA sources included blood and lymphoblastoid cell lines. Subjects were genotyped at the 
Center for Inherited Disease Research (CIDR) using Illumina HumanHap1M Bead-Chips; data 
cleaning has been described [24].   
COLLABORATIVE GENETIC STUDY OF NICOTINE DEPENDENCE  
(COGEND) [26-27] 
The Collaborative Genetic Study of Nicotine Dependence (COGEND) is a United States multi-
site project. Subjects were recruited from St. Louis, Detroit, and Minneapolis through 
community-based telephone screening to determine eligibility for the study.  
Semi-Structured Assessment of Nicotine Dependence (SSAND) was used to obtain phenotypic 
variables. Diagnoses and Statistical Manual of Mental Disorder IV (DSM-IV) lifetime diagnoses 
for alcohol, nicotine, cannabis, cocaine, and opiate were assessed using SSAND. In addition to 
DSM-IV diagnoses, nicotine dependences from Fagerström Test for Nicotine Dependence 
(FTND) and Cigarettes Per Day (CPD) measures were assessed as well. Lifetime exposure was 
also reported in SSAND for all five substances 
For this meta-analysis, COGEND contributed a sample of 1877 unrelated European-Americans 
who were genotyped for rs1799971. The study obtained informed consent from participants and 
approval from the appropriate institutional review boards. 
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DNA was derived from whole blood maintained by the Rutgers University Cell and DNA 
Repository following stringent quality control and assurance procedures (www.rucdr.org).  
Genotyping of the DNA samples was carried out using Perlegen, Illumina GoldenGate, and 
Sequenom MassArray iPLEX technology.  Cleaning procedures have been detailed [27-28].  
Briefly, DNA samples with call rates < 90% were dropped; SNPs were required to pass a call 
rate threshold of 98%; self-reported race was verified using EIGENSTRAT [29]. 
FINNISH HEALTH 2000 [30-31] 
Finnish Health 2000 Study [32] is a nationwide health interview and examination survey carried 
out in Finland in 2000-2001. A representative sample of 8028 adults, aged 30 and over, living in 
the mainland of Finland was produced by using two-stage stratified cluster sampling design (by 
the 5 university hospital regions with16 health care districts selected per region, each region 
containing about 1 million inhabitants i.e. 1/5 of the population). The ethics committees of the 
National Public Health Institute and the Helsinki and Uusimaa Hospital District accepted the 
ethical approval of the survey, and all participants (N=7415) provided a written informed 
consent. 
The lifetime diagnoses for alcohol, cannabis, opiate, and cocaine dependencies based on 
Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), were assessed 
using the computerized version of the Composite International Diagnostic Interview (M-CIDI). 
Overall, 5955 individuals took part to the M-CIDI diagnostic mental health interview, filled in a 
self-report of the seasonal changes in mood and behavior and gave venous blood samples for 
DNA extraction. From these individuals, 522 cases met the diagnostic criteria for alcohol 
dependence (422) or alcohol abuse (100). In addition, 517 healthy (DSM-IV) individuals 
matched by age and gender were selected as the controls. There were 101 women in both groups. 
In addition to DSM-IV diagnoses, as part of the survey participants answered to the questions 
“Have you smoked at least 100 times during your life time (cigarettes, cigars or pipe tobacco)?” 
and “How much on average do you smoke daily or smoked before you gave up smoking daily 
(factory-made cigarettes, self-rolled cigarettes, pipe tobacco, cigars)?”. The latter question was 
recoded to the two-level cigarettes-per-day (CPD) variable. 
For this meta-analysis, Finnish Health 2000 survey contributed rs1799971 genotypes for 1025 
samples. Genomic DNA was isolated from whole blood using standard procedures. Genotyping 
was carried out using TaqMan® technology and Applied Biosystems 7300 Real Time PCR 
System. 2% of the samples were re-genotyped to confirm the precision of genotyping. For the 
analysis of alcohol dependence, the subjects with alcohol abuse diagnosis were excluded. 
FAMILY STUDY OF COCAINE DEPENDENCE (FSCD) [33-34] 
For FSCD study, cocaine-dependent cases were recruited systematically from chemical 
dependency treatment units in the greater St Louis metropolitan area. Community-based control 
subjects were identified through the Missouri Family Registry and matched by age, race, gender 
and residential zip code. Controls were biologically unrelated individuals from the same 
communities who consumed alcohol, but had no life-time history of dependence on any 
substance. 
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The study participants were assessed using psychiatric, lifetime diagnostic interview based on 
the Semi-Structured Assessment for the Genetics of Alcoholism. Informed consent was obtained 
from all participants by trained research assistants. 
  
As part of GENEVA, DNA samples were genotyped on the Illumina Human 1M-Duo beadchip 
by the Center for Inherited Disease Research (CIDR) at Johns Hopkins University. The Illumina 
1M–Duo array has a total of 1 072 820 probes, of which 23 812 are ‘intensity-only’, leaving 1 
049 008 probes as SNP assays. These SNP assays demonstrate excellent data quality—95% of 
SNPs have a missing call rate <1.4% and the median of the missing call rate is 0.05%. A 
thorough data cleaning procedure was applied to ensure the highest possible data quality, 
including the use of HapMap controls, detection of gender and chromosomal anomalies, hidden 
relatedness, population structure, missing call rates, batch effects, Mendelian error detection, 
duplication error detection and Hardy–Weinberg equilibrium. Of the 1 049 008 SNPs, 948 658 
SNPs passed data cleaning procedures. Further details are provided in the comprehensive data 
cleaning report posted on the GENEVA website 
(http://www.genevastudy.org/docs/GENEVA_Alcohol_QC_report_8Oct2008.pdf). 
FINNTWIN12 STUDY (FT12) [35-36] 
FT12 is a longitudinal birth cohort study of Finnish twins, born 1983-1987. Baseline 
questionnaire assessments of ca. 2,600 twin pairs were made in the year before the twins reached 
age 12 [35]. In a second, intensive study phase, 1852 twins who were mostly selected randomly 
but also included families considered to be at risk for alcohol problems were interviewed at age 
14.This sample was followed-up as young adults, including a structured psychiatric interview, 
clinical examinations, neuropsychological testing and blood draw for genetic analyses.  
The FT12 study provided information on nicotine, alcohol, cannabis, cocaine and opiate 
dependence, based on the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA) 
[25, 37]. With the exception of nicotine, DSM-IV lifetime diagnoses for substance dependence 
were assessed using SSAGA. Nicotine dependences from Fagerström Test for Nicotine 
Dependence (FTND) and Cigarettes Per Day (CPD) measures were assessed. Lifetime exposure 
for all five substances was also reported in SSAGA. All data-collection procedures were 
approved by the Ethics committee of the Hospital District of Helsinki and Uusimaa, and the IRB 
of Indiana University, Bloomington, IN,  including the use of appropriate and approved 
informed-consent procedures. 
In the FT12 study, a total of 872 Finnish young adult twins were genotyped for rs1799971. For 
this meta-analysis, one twin from pairs in which both co-twins were genotyped was randomly 
selected for the analyses. This resulted in a sample of 617 unrelated twins (52.0% females) 
whose mean age at assessment was 22.4 years (sd=0.7 yrs, range: 19.9–26.5 yrs).  
DNA was extracted from blood and saliva samples using standard procedures. Genotyping  and 
quality control was performed at the Welcome Trust Sanger Institute (Hinxton, UK) on the 
Human670-QuadCustom Illumina BeadChip (Illumina, Inc., San Diego, CA, USA), as 
previously described [36]. 
THE GENETICS OF ANTISOCIAL DRUG DEPENDENCE (GADD) [38] 
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538 unrelated European American and 102 unrelated African American subjects were drawn 
from the Genetics of Antisocial Drug Dependence (GADD) [39] sample encompassing over 
4,000 subjects. Unrelated subjects were drawn from the whole sample by randomly selecting one 
member per family using Statistical Analysis System (SAS) 9.3 software (SAS Institute Inc., 
Cary, NC). The GADD sample consists of clinical probands, aged 14-19 at first assessment, their 
siblings, and one or both biological parents.  Probands in Denver, CO, and San Diego, CA, were 
identified from treatment programs, involvement with the criminal justice system, or special 
schools who had at least one lifetime substance dependence symptom (other than nicotine 
dependence) and at least one symptom of conduct disorder. The GADD is a longitudinal study in 
the 2nd wave of data collection; wave 1 was collected between 2001 and 2006, and wave 2, 
collection of which began in 2009, is currently ongoing. Only data from the completed wave 1 
was used in the current study. All study participants were given cognitive, psychiatric, and socio-
demographic assessments that included both structured diagnostic interviews as well as self-
reported questionnaires. The University of California and the University of Colorado IRBs 
approved all subject recruitment, assessment, and DNA collection procedures.  
Substance use patterns were assessed with the Composite International Diagnostic Interview—
Substance Abuse Module (CIDI-SAM), a structured, face-to-face diagnostic assessment 
designed to be administered by trained, lay interviewers [4]. This assessment procedure has been 
shown to be valid for adolescent subjects [5]. The following DSM-IV substance dependence 
phenotypes were assessed: nicotine dependence, alcohol dependence, opioid dependence, 
cocaine dependence, and cannabis dependence. The interview includes substance use patterns, 
from which the phenotype of cigarettes per day was derived.  
DNA was obtained with consent through either buccal cells or blood. SNP genotyping on 3,072 
subjects was performed with TaqMan©® assays for allelic discrimination according to 
manufacturer’s instructions (Applied Biosystems, Foster City, California). Polymerase Chain 
Reaction (PCR) reactions were performed with the Biomek® 3000 Laboratory Automation 
Workstation (Beckman Coulter Inc, Brea, California) and the Dual 384-Well GeneAmp® PCR 
system 9700 (Applied Biosystems, Foster City, California). To analyze the amplified plates the 
7900 Real-Time PCR System (Applied Biosystems, Foster City, California) was used. QC 
performed on the genotyped sample excluded individuals with fewer than 90% genotypes across 
all SNPs ever genotyped in this sample (N = 170; assumed poor quality DNA sample). Two 
independent individuals called all SNP genotypes; if genotype calls did not agree they were 
excluded. 
GERMAN STUDY OF THE GENETICS OF ADDICTION (ALCOHOLISM) (GESGA) 
[40-41] 
The German Study of the Genetics of Addiction (Alcoholism) (GESGA) is a German multi-
center project. All patients fulfilled DSM-IV criteria for alcohol dependence and were recruited 
through consecutive admissions to the psychiatry and addiction medicine departments of German 
psychiatric hospitals participating in the German addiction research network [41]. 
Control individuals were drawn from several population based epidemiologic / community based 
German samples [40-41]. 
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For this meta-analysis, GESGA contributed a sample of 3501 unrelated German individuals who 
were genotyped for rs1799971. The study obtained written informed consent from participants 
and approval from the appropriate institutional review boards. 
DNA was derived from whole blood according to standard procedures. Genotyping of the DNA 
samples was carried out using Illumina HumanHap 550, Human610quad and Human660w quad 
bead chips.  Cleaning procedures have been detailed [40-41].  Briefly, DNA samples with call 
rates < 98% were dropped; SNPs were required to pass a call rate threshold of 98%; self-reported 
ancestry was verified using EIGENSTRAT [29].  
THE LABORATORY OF THE BIOLOGY OF ADDICTIVE DISEASES (Kreek) [42] 
The “Kreek” sample includes unrelated former severe heroin addicts (cases) and normal 
volunteers (controls). Cases were treated at a methadone maintenance treatment program 
(MMTP) at the time of recruitment and had one or more years of daily multiple uses of heroin.  
Subjects were recruited at either the Rockefeller University Hospital or MMTPs (e.g. Manhattan 
Campus of VA NY Harbor Health Care System, Weill Medical College of Cornell University), 
and the Adelson Clinics for Drug Abuse Treatment and Research, in Las Vegas. Exclusion 
criteria from Control category: a) At least one instance of drinking to intoxication, or any illicit 
drug use in the previous 30 days; b) A past history of alcohol drinking to intoxication, or illicit 
drug use, more than twice a week, for more than 6 consecutive months; and c) Cannabis use for 
more than 12 days in the prior 30 days or past use for more than twice a week for more than 4 
years (e.g. [43]). The following instruments were used: Addiction Severity Index (ASI) [44], 
KMSK [45], DSM-IV and  a family history questionnaire of three generations. 
For this meta-analysis, KREEK contributed a sample of 750 unrelated European-Americans (528 
heroin dependents and 222 controls) who were genotyped for rs1799971. The study obtained 
informed consent from participants and approval from the appropriate institutional review board. 
DNA was derived from whole blood following stringent quality control and assurance 
procedures.  Genotyping of the DNA samples was carried out using Illumina GoldenGate [46], 
Taqman® and/or Sanger sequencing.  Cleaning procedures have been detailed [42].  Self-
reported race was verified using a family history questionnaire and  STRUCTURE analysis of 
178 AIMs [47].  
THE MINNESOTA CENTER FOR TWIN AND FAMILY RESEARCH (MCTFR) [48-51] 
The Minnesota Center for Twin and Family Research (MCTFR) is a Minneapolis-based project. 
Participants from twin, adoptive, and non-adoptive families were recruited from the state of 
Minnesota. Twins were recruited using Minnesota Department of Health birth certificate records. 
Mirroring the population from which the twins were sampled, approximately 95% of the twins 
and their families are of European ancestry. Adoptive families were ascertained through records 
of infant placements made by the three largest private adoption agencies in Minnesota. Non-
adoptive (biological) non-twin families were located from birth certificates with families 
sampled randomly to obtain families with children matching the age and gender distribution of 
the adoptive children. While the majority of the parents in this non-twin-family sample are 
White, just under 40% of the siblings are East Asian. Study eligibility was established through 
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phone contact and a biographical questionnaire, and adolescents with mental or physical 
limitations that would hinder their ability to complete assessments (e.g., mental retardation, 
autism, blindness, etc.), who did not live with at least one biological parent if not adopted or at 
least one adoptive parent if adopted, or who lived more than a day’s drive from the University of 
Minnesota's Minneapolis campus, were not recruited. No other exclusion criteria, including race 
or ethnic origin, were applied. Additional description of the MCTFR samples and procedures is 
given in [48-50].  Participants gave informed consent to participate in the MCTFR assessments, 
or in the case of minor children assent along with parental consent. MCTFR protocols, including 
those used in the genotyping analysis, have been approved by the University of Minnesota’s 
Institutional Review Board. 
For this meta-analysis, the MCTFR contributed a sample of 3846 European-Americans 
selected from among the parents in the MCTFR studies who had been genotyped for rs1799971.  
Participants in the meta-analysis were not genetically related to one another but may have been 
married. Individuals all completed a structured clinical interview administered by a trained 
interviewer and lifetime diagnoses for alcohol, nicotine, cannabis, cocaine, and opiate 
dependence were made in a consensus case conference according to Diagnostic and Statistical 
Manual of Mental Disorders IV (DSM-IV) criteria. 
DNA was derived from whole blood or saliva and extracted and stored at the Rutgers 
University Cell and DNA Repository following stringent quality control and assurance 
procedures (www.rucdr.org). Samples were genotyped on 657,366 markers (including 95,876 
intensity-only markers) using the Illumina Human 660W-Quad array (Illumina, Inc., San Diego 
CA) following standard protocol. Details concerning the quality control procedures used with 
both markers and samples is given in [51]. Briefly, samples were eliminated because of: 1) low 
call rate; 2) low GenCall score; 3) extreme heterozygosity or homozygosity; and 4) sample mix-
ups. Markers were eliminated because the marker had: 1) been identified as problematic by 
Illumina; 2) more than one mismatch in duplicated samples; 3) a call rate < 99%; 4) a minor 
allele frequency < 1%; 5) more than two Mendelian inconsistencies; 6) deviation from Hardy-
Weinberg equilibrium at p < 10-7; and 7) an association with participant sex or batch at   p < 10-7. 
European ancestry was based on self-report, confirmed through an EIGENSTRAT analysis [29] 
as detailed in [51]. 
NICOTINE ADDICTION GENETICS (NAG) PROJECT AND AUSTRALIAN BIG 
SIBSHIP PROJECTS (NAG-AUS/BIGSIB; NAG-FIN) [52-53]  
The study participants for the Nicotine Addiction Genetics Project (NAG) were enrolled at two 
different sites: the Queensland Institute of Medical Research (QIMR) in Australia and the 
University of Helsinki (UH) in Finland. Families for both the Australian and Finnish arms of the 
NAG were identified through smoking index cases by use of previously administered interview 
and/or questionnaire surveys of the community-based Australian and population-based Finnish 
registers of twins [52-53]. The Finnish arm of the NAG project (NAG-F IN, see above for 
detailed description) recruited families from the Finnish Twin Cohort, which consists of all 
Finnish twin pairs born between 1938 and 1957 [35]. Families chosen for the Australian arm of 
the NAG study (NAG-Aus) were identified from two cohorts of the Australian Twin Panel, 
which included spouses of the older of these two cohorts. The ancestry of the Australian samples 
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is predominantly Anglo-Celtic or northern European (>90%). We also used data obtained from a 
third Australian Community-based family study, the Australian Big Sibship (BigSib). The 
BigSib sample comprises families ascertained through the Australian Twin Panel selected for 
five or more offspring sharing both biological parents. Families for the BigSib sample were 
recruited from the same Australian Twin Panel sources as were the NAG Australian families, 
and phenotypic information was obtained using the same assessment protocol as for the NAG. 
Clinical data for both Australian and Finnish subjects were collected using a computer-assisted 
telephone diagnostic interview (CATI), and adaptation of the Semi-Structured Assessment for 
the Genetics of Alcoholism (SSAGA) [25, 37] for telephone administration. The tobacco section 
of the CATI was derived from the Composite International Diagnostic Interview (CIDI) [54] and 
incorporated standard FTND, DSM-III-R, and DSM-IV assessments of nicotine dependence. It 
also included a detailed history of cigarette and other tobacco use, including quantity and 
frequency of use for current, most recent, and heaviest period of use. The measure examined for 
the purposes of this study was the number of cigarettes smoked per day, during heaviest period 
of use. All data-collection procedures were approved by institutional review boards at 
Washington University (WU), the QIMR, and the Ethics committee of the Hospital District of 
Helsinki and Uusimaa, including the use of appropriate and approved informed-consent 
procedures.    For this meta-analysis, NAG/BigSib-Aus combined sample contributed 
information from a total of 1329 unrelated adult subjects (about 40% women; including 45% 
from the BigSib sample), 18-82 years of age (mean age: 44 years) at the time of assessment; 
including 592 who reported smoking 10 or fewer cigarettes per day, 489 subject who reported 
smoking 20 to 39 per day, and 248 Australians who reported smoking 40 or more cigarettes per 
day during their heaviest period of smoking. Participants gave informed consent for an interview, 
for providing a blood sample for DNA extraction and cell lines, and for the sharing of their 
anonymous clinical and genotypic records with scientists outside of the NAG and/or BigSib 
research teams of investigators. 
NICOTINE ADDICTION GENETICS - FINLAND STUDY (FTC/NAG-FIN) [52]  
The FTC/NAG-FIN sample was ascertained from the Finnish Twin Cohort study consisting of 
adult twins born between 1938 and 1957 (www.twinstudy.helsinki.fi). Based on earlier health 
questionnaires, the twin pairs concordant for ever smoking were identified and recruited along 
with their family members (mainly siblings) for the Nicotine Addiction Genetics Finland study 
(N = 2,265), as part of the consortium including Finland, Australia, and United States (see NAG-
AUS below) [52]. Data collection took place between 2001 and 2005. 
The NAG-FIN study provided information on nicotine and alcohol dependence, based on an 
adaptation of the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA) [25, 37] 
for telephone administration. DSM-IV lifetime diagnoses for alcohol and nicotine were assessed 
using SSAGA. In addition to DSM-IV diagnoses, nicotine dependences from Fagerström Test 
for Nicotine Dependence (FTND) and Cigarettes Per Day (CPD) measures were assessed. CPD 
was based on quantity and frequency of use during the heaviest period of use. Lifetime exposure 
for nicotine and alcohol was also reported in SSAGA. Use and dependence on cannabis and 
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illicit drugs were asked, but the prevalence was low. All data-collection procedures were 
approved by the Ethics committee of the Hospital District of Helsinki and Uusimaa and the IRB 
at Washington University, St. Louis, MO, including the use of appropriate and approved 
informed-consent procedures. 
In the NAG-FIN study, a total of 1,387 Finnish adult twins were genotyped for rs1799971. For 
this meta-analysis, one twin from pairs in which both co-twins were genotyped was randomly 
selected for the analyses. This resulted in a sample of 879 unrelated twins (30.0% females) 
whose mean age at assessment was 54.9 years (sd=4.5 yrs, range: 42.0–76.6 yrs).  
DNA was derived from blood samples taken at local health centres and shipped overnight to the 
National Institute for Health and Welfare. DNA was extracted by standard methods and 
genotyping  was performed at the Welcome Trust Sanger Institute (Hinxton, UK) on the 
Human670-QuadCustom Illumina BeadChip (Illumina, Inc., San Diego, CA, USA), with quality 
control methods as previously described [36]. 
NATIONAL YOUTH SURVEY – FAMILY STUDY (NYSFS; ORIGINALLY 
“NATIONAL YOUTH SURVEY”) (NYS) [55-57] 
The National Youth Survey began in 1977.  At that time 1,725 adolescents between the ages of 
11 and 17 years old as well as one of their parents were interviewed. Participants were chosen by 
a scientific method designed to select individuals who were representative of the national 
population.  It was a sample of households with all children between 11 and 17 within a chosen 
household recruited.  It is a longitudinal study, with 12 waves of interviews conducted.  DNA for 
1,072 individuals was collected as part of wave 10 interviews [55-57]. Subjects without 
genotypic information (N = 82) or phenotypic data (N = 16) were removed from the analysis.  Of 
the remaining 974 individuals, 770 were European American and 120 were African American.  
Because the original ascertainment methods included all children in the household, we used SAS 
proc surveyselect to identify the subset of unrelated individuals used in this study (European 
American N = 552, African American N = 77). All research protocols and consent forms were 
approved by the institutional review board of the University of Colorado. Phenotypic data used 
in this study were from the wave 10 data collection, when the initial probands were 37-43 years 
old.  Subjects were assessed with the Composite International Diagnostic Interview-Substance 
Abuse Module (CIDI-SAM). Cigarettes per day was defined as the number of cigarettes smoked 
per day at the time when the individual smoked the most in his/her lifetime.  Alcohol, cocaine, 
nicotine, opioid, and cannabis DSM-IV dependence were derived from the CIDI-SAM.DNA was 
derived from buccal cells.  A TaqMan assay performed on a ABI PRISM© 7900 (Applied 
Biosystems, Foster City, CA) was used to determine the genotype. For QC, genotypes were 
called independently by two individuals.  Samples that were unable to be genotyped (assumed 
poor quality DNA) or for which two independent callers disagreed were removed from the 
analysis. 
OREGON YOUTH SUBSTANCE USE PROJECT (OYSUP) [58]  
The Oregon Youth Substance Use Project is a fifteen-year ongoing longitudinal study of 
approximately 1000 participants examining the etiology of substance use in Oregon youth [58]. 
OYSUP began in the 1997-1998 school year with students in five grade cohorts in the first 
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through fifth grade, recruited from a single school district in a working class community in 
Western Oregon. Using a stratified random sample, parents of 2,127 students in 15 elementary 
schools were sent a letter followed by a phone call describing the project and soliciting 
participation. We obtained parental consent for 1075 students (50.7%) to participate in 
assessments for the first four years of the study. An average of 215 students per grade (1st 
through 5th) participated in the study in the first year with an even distribution by gender (50.3% 
female, N=538). Participants were comparable to elementary students in the district on 
race/ethnicity and participation in the free-lunch program [58]. However, they had significantly 
higher scores (albeit a small absolute difference) on academic achievement tests in both reading 
and math. Students in the study were comparable to students in Oregon on 30 day prevalence of 
use of all substances in the 6th grade (DHS, State of Oregon, 2000), with the exception of 
inhalants, where the prevalence of inhalant use was slightly higher in Oregon than in the OYSUP 
sample.   
Lifetime smoking status was defined by an affirmative to the question, “Have you ever smoked 
at least 100 cigarettes in your lifetime?”. Current smoking status was defined by an indication of 
at least one cigarette in answer to the question, “During the past seven days, how many cigarettes 
did you smoke on a typical day?”. Alcohol abuse or dependence diagnoses were based on the 
structured clinical interview for DSM-IV Axis 1 disorders, the SCID-I [59].  A lifetime diagnosis 
was defined as the presence of abuse and/or dependence at any time during the participant’s life, 
and a current diagnosis was defined based on abuse and/or dependence on alcohol present during 
the last six months.  
The study cohort of 404 individuals were aged 21 – 23 within two grade-based cohorts from the 
OYSUP. Appropriate institutional review board approval was obtained from the Oregon 
Research Institute and SRI International. We collected saliva for analysis of salivary DNA from 
OYSUP participants in the afternoon at least two hours after the participant had eaten lunch as 
described [60]. Saliva biospecimens for DNA extraction were collected using commercially 
available kits for saliva collection using the manufacturer’s protocol. DNA was extracted for 
N=404 participants using the DNA Genotek protocol modified as described [61]. Samples were 
genotyped using TaqMan® SNP Genotyping assay (Applied Biosystems) C__8950074_1_ for 
OPRM1 rs1799971 on a ViiA™ 7 System (Applied Biosystems) with positive and negative 
controls and 18% duplicates. Genotyping gave 99.8% completion rate with a minor allele 
frequency of 0.125 and was in Hardy-Weinberg Equilibrium. Regenotyped samples gave 100% 
concordance rate with original genotypes. 
MUNICH GERMANY (PAGES) [62] 
Individuals with schizophrenia were ascertained from the Munich area in Germany. Of this 
sample, 71% were of German descent and 29% were Caucasian middle Europeans. Case 
participants had a DSM-IV and ICD-10 diagnosis of schizophrenia with the following subtypes: 
paranoid 78.2%, disorganized 16.7%, catatonic 0.5% and undifferentiated 4.6%. Detailed 
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medical and psychiatric histories were collected, including a clinical interview using the SCID, 
to evaluate lifetime Axis I and II diagnoses. Four physicians and one psychologist rated the 
SCID interviews, and all measurements were double-rated by a senior researcher. Exclusion 
criteria included a history of head injury or neurological diseases. All case participants were 
outpatients or stable inpatients. Further details can be found in previous reports [62]. 
The Structured Clinical Interview for DSM-IV (SCID I and SCID II) [59, 63] was used to obtain 
Statistical Manual of Mental Disorder IV (DSM-IV) lifetime diagnoses for alcohol, cannabis, 
cocaine, and opiate. Nicotine dependences from Fagerström Test for Nicotine Dependence 
(FTND) and Cigarettes Per Day (CPD) measures were assessed as well.  
For this meta-analysis, the German sample contributed unrelated European Caucasians (414 
schizophrenia patients).  The study obtained informed consent from participants and approval 
from the appropriate institutional review boards.  
DNA was obtained from peripheral blood. DNA concentration was adjusted using the PicoGreen 
quantitation reagent (Invitrogen, Karlsruhe, Germany), and 1 ng was genotyped using the iPLEX 
assay on the MassARRAY MALDI-TOF mass spectrometer (SEQUENOM, Hamburg, 
Germany). Genotyping call rates in cases and controls were all >97%. Allele frequencies were 
similar to CEU sample frequencies. A subsample of SNPs and DNA was genotyped twice to 
check for genotyping errors. 
PATCH IN PRACTICE (PiP) [64] 
The Patch in Practice cohort is drawn from participants in a randomised controlled trial of two 
levels of behavioural support offered in conjunction with nicotine transdermal patch in Primary 
Care, conducted in 2002-2005, which recruited n = 935 heavy smokers (≥ 10 cigarettes per day). 
Participants were given sufficient patches for 8 weeks. Abstinence from smoking at 1-week, 2-
week and 4-week follow-up was confirmed by expired carbon monoxide concentration (≤ 10 
ppm), and at 12-week, 26-week and 1-year follow-up by salivary cotinine concentration (≤ 15 
ng/ml). Data collected at baseline included age in years, sex, body mass index in kg/m2, self-
reported ancestry and self-reported smoking habits, including a measure of nicotine dependence 
using the Fagerström Test for Nicotine Dependence. All participants provided a blood sample 
collected by the participant’s GP or practice nurse. Ethics approval was obtained from the 
appropriate NHS Research Ethics Committee, and informed consent procedures were followed. 
Genotyping was conducted as previously described [64]. 
SMOKING IN FAMILIES (SMOFAM) [65-69] 
The Smoking in Families study is a longitudinal, repeated measures age-sequential cohort study 
of environmental and psychosocial risk factors for adolescent and young adult substance use, 
including tobacco use and dependence, initiated in 1984 [65]. Subjects were recruited through 
advertisements in traditional media, and flyers distributed at middle and high schools in four 
mid-sized and small urban and rural Pacific Northwest cities with populations ranging from 
30,000 to 175,000. The original SMOFAM study recruited 763 families, with at least one 
adolescent age 11 or older. Families with smoking parents and/or adolescents were of special 
interest since the focus was on adolescents at risk for tobacco and other substance use. Within 
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each family one adolescent was designated as the proband if s/he had previously tried a 
substance. Each proband had to have at least one parent agree to participate. An attempt was 
made to encourage both parents and all sibs over the age of 11 to participate. The only other 
requirement was that all participants needed to be able to read basic level English. Repeated 
annual assessment of probands facilitated characterization of longitudinal phenotypes for tobacco 
use, including the acquisition and maintenance of smoking, as well as many potential 
psychosocial and environmental predictors of substance. Probands and two first-degree relatives 
from 158 pedigrees with at least three ever-smoking individuals per pedigree were recruited from 
SMOFAM to study the environmental, genetic and metabolic determinants of tobacco use, 
completed a detailed smoking history questionnaire including cigarettes per day and the 
Fagerström Test for Nicotine Dependence, and provided a whole blood sample for DNA 
extraction and analysis [66]. All family members gave written informed consent to search for 
genes related to the development of nicotine dependence. Institutional review boards at Oregon 
Research Institute, SRI International and the University of California San Francisco gave 
approval to conduct the research. DNA was genotyped using a custom GoldenGate assay of 1536 
SNPs, including rs1799971, to interrogate cholinergic and dopaminergic candidate genes [67], 
with quality control measures relating to replicate DNA samples and control DNA samples as 
described [68], and where genotype errors based on Mendelian inconsistency were evaluated 
using Pedcheck and Merlin as described [69]. Randomly chosen unrelated individuals with 
complete genotype data were selected from each pedigree for analysis. 
THE UTAH GENETICS OF ADDICTION PROJECT (UTAH) [70] 
The Utah Genetics of Addiction Project contributed the Utah cohort from a study of genetic risk 
markers for nicotine dependence and chronic obstructive pulmonary disease (COPD) [70].  The 
UT cohort was made up of respondents to community advertising for persons who had smoked 
more than 100 cigarettes lifetime plus a subset of Lung Health Study (LHS) participants 
originally recruited in Utah.  UT participants were not drawn from a psychiatric treatment 
population, and no medical or behavioral treatments were offered as part of the study.  UT 
volunteers were not excluded simply because they had a lifetime diagnosis of psychosis or 
Bipolar Disorder, but they were excluded if their current mental status made it impossible for 
them to complete the questionnaires or interviews.  Pulmonary function testing determined 62% 
of the UT cohort had COPD.  Of UT participants, 43% had not smoked for at least 2 years prior 
to participation in the study.  All UT participants were of European descent, and all had smoked 
more than 100 cigarettes lifetime. DSM-IV Substance Dependence diagnoses were based on 
SCID-I/P (2001 Final Version) interviews conducted by a clinical research psychologist.  Study 
procedures were approved by the University of Utah IRB.  DNA was isolated from peripheral 
blood lymphocytes collected in Salt Lake City, UT (UT cohort). SNP genotyping methods were 
previously described56 and used the SNPlex assay (Applied Biosystems).  
VIRGINIA ADULT TWIN STUDY OF PSYCHIATRIC AND SUBSTANCE USE 
DISORDER (VA-Twin) [71-73] 
The VA-Twins were selected from the Virginia Adult Twin Study of Psychiatric and Substance 
Use Disorder, which was a population-based epidemiology study. Tobacco smoking and nicotine 
dependence were assessed by the Fagerström Tolerance Questionnaire (FTQ) and/or Fagerström 
Test for Nicotine Dependence (FTND) during the time of heaviest lifetime nicotine use. In this 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
18 
 
study, only regular smokers (defined as those who used at some point in their lives an average of 
at least seven cigarettes per week for a minimum of four weeks) were included (N = 2388). One 
subject from each twin pair was selected, and all subjects were of Caucasian ancestry. The study 
obtained informed consent from participants and approval from the institutional review board of 
Virginia Commonwealth University. DNA was extracted from buccal brushes. Genotyping was 
performed with the TaqMan genotyping method.  To ensure the quality of genotyping, negative 
control samples were included in each plate. Genotypes were scored using a semi-automated 
protocol [74].  
YALE-PENN [75-77] 
Yale-Penn study participants were recruited for studies of the genetics of drug (opioid or 
cocaine) or alcohol dependence. Subjects were recruited at five eastern US sites: Yale University 
School of Medicine (APT Foundation, New Haven, CT), University of Connecticut Health 
Center (UConn, Farmington, CT), Medical University of South Carolina (MUSC, Charleston, 
SC), McLean Hospital (Harvard Medical School; Belmont, MA), and the University of 
Pennsylvania (Philadelphia, PA). Informed consent procedures were followed for this study. 
Genetic studies of substance dependence disorders and related traits in a subset of this sample have been 
published [75-77]. 
 
All subjects were interviewed using an electronic version of the Semi-Structured Assessment for 
Drug Dependence and Alcoholism (SSADDA) [78-79] to derive diagnoses for lifetime substance 
dependence (alcohol, nicotine, cannabis, cocaine and opioid) and other major psychiatric traits 
according to DSM-IV criteria. The FTND items were embedded directly in the SSADDA 
assessment. CPD was derived directly from the FTND question: “When you were smoking 
regularly, how many cigarettes did you usually smoke in a day?” Subjects were excluded from 
further study if they had ever received a clinical diagnosis of a major psychiatric illness often 
associated with psychotic episodes (i.e., schizophrenia, schizoaffective, or bipolar disorder) 
 
A total of 2133 African Americans and 1218 European Americans were genotyped from cell 
lines, blood and in a small number of cases, saliva. Genotyping was done on the Illumina 
HumanOmni1-Quad v1.0 microarray containing 988,306 autosomal SNPs. GWAS genotyping 
was conducted at the Center for Inherited Disease Research (CIDR) and the Yale Center for 
Genome Analysis. Genotypes were called using GenomeStudio software V2011.1 and 
genotyping module V1.8.4 (Illumina, San Diego, CA, USA). 
 
A total of 44,644 SNPs on the microarray and 135 individuals with call rates < 98% were 
excluded, and 62,076 additional SNPs were removed due to minor allele frequencies (MAF) 
<1%. We identified several instances where identical DNA marker profiles were linked to two 
different interview forms. When demographic information (sex, date of birth, number of reported 
children) was consistent across interviews, one sample was randomly removed from analysis.  
When demographic information was inconsistent across interviews, both samples were removed. 
Reported sex was verified based on the computed average X chromosome heterozygosity; self-
reported males with heterozygosity of more than 20% and self-reported females with 
heterozygosity less than 20% were excluded unless their true identity could otherwise be 
reconciled. QC is described in more detail in Gelernter et al [75-77]. 
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Supplementary Text S2: Power calculation details. 
All power calculations were performed using Quanto (Gauderman and Morrisson, 
http://biostats.usc.edu/software.html). 
1. Power for prior GWAS consortia meta-analyses of smoking ([1-3]) to detect OPRM1. 
Parameters: 
Disease allele frequency: 0.15 
Odds Ratio: 0.93 (nicotine-specific odds ratio in Table 3; reciprocal is 1/0.93 = 1.075) 
Log additive disease model (for analysis of heavy-smoking cases and light-smoking controls)  
Ratio of cases to controls: 1:1 (maximizes power at a fixed total sample size) 
Population risk: 0.20 
2-sided test 
 
Sample sizes of the 3 consortia: 
1. TAG [1]: N=38,000 (19,000 case-control pairs). 
2. ENGAGE [2]: N=31,000 (15,500 case-ctrl pairs). 
3. Ox-GSK [3]: N=16,000 (8,000 case-control pairs). 
 
OPRM1 was tested only in the 3 consortia separately; it was not meta-analyzed across all 3 
consortia combined.  Meta-analysis across all 3 consortia was performed only for selected top 
loci in each consortium.  
 
Thus we computed  
(1) The power to detect this OPRM1 effect in at least one of the 3 consortia at genome-wide 
significance (alpha = 5 x 10-8) 
(2) To approximate the power for at least one of the 3 consortia to have selected OPRM1 for 
follow-up meta-analysis across all 3 consortia, we relaxed the significance threshold to alpha = 3 
x 10-5. Based on supplementary tables in [1-3], the threshold was in fact more stringent for 
ENGAGE [2] and Ox-GSK [3], and unclear for TAG [1].  
(3) Even though rs1799971 was not tested across the three consortia combined, for comparison 
we calculated power to detect OPRM1 in the combined consortia (N=85,000). 
 
Power result 1:  Power for genome-wide significance (alpha = 5 x 10-8) in at least one of the 3 
consortia is 4%: 
 
Sample sizes and corresponding power for each individual consortium at alpha = 5 x 10-8: 
1. TAG [1]: N=38,000 (19,000 case-control pairs), corresponds to 2.8% power. 
2. ENGAGE [2]: N=31,000 (15,500 case-ctrl pairs) gives 1.2% power 
3. Ox-GSK [3]: N=16,000 (8,000 case-control pairs) gives 0.08% power 
 
Then, the power to detect OR=0.93 at GWAS significance in at least one of the 3 consortia is 
given by the formula  
Power  = 1-(1-(power to detect in TAG alone))*(1-(power to detect in ENGAGE alone)) 
*(1-(power to detect in Ox-GSK alone))  
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= 1 - (1 - 0.028)*(1 - 0.012)*(1 - 0.0008)  
= 1-(0.972)(0.988)(0.9992)  
= 1-0.95956  
= 0.040  
= 4.0% power. 
 
Power result 2: Power to detect this effect for follow-up in at least one of the 3 consortia is 40%: 
 
Sample sizes and corresponding power for each individual consortium at alpha = 3 x 10-5: 
1. TAG [1]: N=38,000 (19,000 case-control pairs), corresponding to 26.45% power. 
2. ENGAGE [2]: N=31,000 (15,500 case-ctrl pairs), giving 16.5% power 
3. Ox-GSK [3]: N=16,000 (8,000 case-control pairs), giving 3.05% power 
 
Then, the power to detect OR=0.93 at 5 x 10-5 in at least one of the 3 consortia is given by the 
formula  
Power  = 1-(1-(power to detect in TAG alone))*(1-(power to detect in ENGAGE alone)) 
*(1-(power to detect in Ox-GSK alone))  
= 1 - (1 - 0.2645)*(1 - 0.165)*(1 - 0.0305)  
= 1 – (0.7355)(0.835)(0.9695)  
= 1-(0.59541115375)  
= 0.40459  
= 40% power. 
 
Power result 3: Rs1799971 was not tested across all three consortia combined. However, if it had 
been, power to detect OR = 0.93 at alpha = 5x10-8 in a combined analysis of N=85,000 is still 
only 43%. 
 
 
2. For comparison: Power of the current targeted study to detect the OPRM1 association with 
general substance dependence (N=16,908 subjects) is 79.6%. 
Parameters: 
Disease allele frequency: 0.15 
Odds Ratio: 0.90 (general substance dependence liability odds ratio, Table 3) 
Log additive disease model 
Ratio of cases to controls: 1:0.8654 (corresponds to 9064 cases, 7844 controls, Table 3) 
Population risk: 0.2 
2-sided test 
N=16,908 total: 9064 cases, 7844 controls 
Required multiple-test corrected p-value is alpha = 0.00976 
Resulting power is 79.6%. 
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Supplementary Figures: Individual Substance Dependence Analyses 
Figure S1. Alcohol Dependence 
 
Figure S1 Forest plot of alcohol dependence and rs1799971 across studies that had at least 5 
cases (participants with DSM-IV alcohol dependent diagnosis) and 5 alcohol-exposed, non-
alcohol-dependent controls (filtered to remove participants who never drank at least one drink in 
lifetime) each. Summary odds ratio, 95% Confidence Interval and p-values are based on fixed 
effect meta-analysis.  
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Figure S2. Cigarettes-per-day (CPD) dichotomized phenotype (heavy vs. light smoking) 
 
Figure S2 Forest plot of CPD dichotomized phenotype (heavy vs. light smoking) and rs1799971 
across studies that had at least 5 cases (participants who smoke more than 20 CPD) and 5 
nicotine-exposed controls (participants who smoke less or equal to 10 CPD and have smoked at 
least 100 cigarettes in lifetime) each. Summary odds ratio, 95% Confidence Interval and p-values 
are based on fixed effect meta-analysis. 
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Figure S3. Cannabis Dependence 
 
Figure S3 Forest plot of cannabis dependence and rs1799971 across studies that had at least 5 
cases (participants with DSM-IV cannabis dependent diagnosis) and 5 cannabis-exposed controls 
(participants with no cannabis dependent diagnosis and have tried cannabis at least once) each. 
Summary odds ratio, 95% Confidence Interval and p-values are based on fixed effect meta-
analysis 
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Figure S4. Cocaine Dependence 
 
Figure S4 Forest plot of cocaine dependence and rs1799971 across studies that had at least 5 cases 
(participants with DSM-IV cocaine dependent diagnosis) and 5 cocaine-exposed controls (participants 
with no cocaine dependent diagnosis and have tried cocaine at least once) each. Summary odds ratio, 95% 
Confidence Interval and p-values are based on fixed effect meta-analysis 
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Figure S5. Opioid Dependence 
 
Figure S5 Forest plot of opioid dependence and rs1799971 across studies that had at least 5 cases 
(participants with DSM-IV opioid dependent diagnosis) and 5 opioid-exposed controls 
(participants with no opioid dependent diagnosis and have tried an opioid at least once) each. 
Summary odds ratio, 95% Confidence Interval and p-values are based on fixed effect meta-
analysis 
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